Erectile dysfunction treatments do not appear to damage vision over 6 months

	Tweet

Two medications used to treat erectile dysfunction in men (tadalafil and sildenafil) do not appear to have visual side effects when taken daily for six months, despite concerns about eye-related complications, according to a report in the April issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

The advent of the medications sildenafil citrate (sold as Viagra), tadalafil (sold as Cialis) and verdenafil hydrochloride (sold as Levitra) has profoundly changed the treatment of erectile dysfunction, according to background information in the article. These medications are known as selective phodiesterase type 5 (PDE5) inhibitors because they treat erectile dysfunction by interfering with the action of the compound PDE5 on the blood vessels in the penis. However, PDE5 inhibitors may also act on similar compounds in the retina, the part of the eye that receives and transmits images. Mild and transient blurred vision, blue-tinged vision and altered light perception have been reported by men taking these drugs, and some visual complications of long-term use have been suggested.

William H. Cordell, M.D., of Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, and colleagues conducted a randomized placebo-controlled study to assess changes in the retina among men taking tadalafil or sildenafil. A total of 244 healthy men, some with mild erectile dysfunction, age 30 to 65 were recruited. 

Of these, 85 were randomly assigned to take 5 milligrams of tadalafil, 77 to take 50 milligrams of sildenafil and 82 to take a placebo daily for six months. The men underwent comprehensive ophthalmologic examinations including electroretinography (a test to measure the electrical response of the light-sensitive rods and cones in the eye, used to detect diseases of the retina) before, during and after treatment.

Among the 194 men (79.5 percent) who completed the study, no significant differences were found between treatment and placebo groups on electroretinography, visual function tests, measurements of intraocular pressure (pressure within the eyeball) or assessments of the anatomy of the eye. Nine participants (two in the placebo group, one in the tadalafil group and six in the sildenafil group) discontinued the study because of an adverse event, but only one of those was an ophthalmologic event (in the placebo group). No abnormalities that would be suggestive of drug toxicity were observed in any of the participants.

“There are several reasons ophthalmologists need to be acquainted with the pharmacologic profiles of PDE5 inhibitors and their potential side effects,” the authors write. “The frequency of erectile dysfunction, which is a form of peripheral vascular disease that impairs men’s abilities to achieve and maintain an erection, increases dramatically with age and in the presence of cardiovascular risk factors. Therefore, many men who take PDE5 inhibitors to treat their erectile dysfunction will also be followed up by ophthalmologists for ocular disorders such as diabetic retinopathy, macular degeneration and ocular vascular disease.”

“Furthermore, PDE5 inhibitors can exert direct effects on the retina, and such effects probably account for many of the visual side effects such as blue-tinged vision and light sensitivity that have been reported,” they conclude. However, “our results indicate that there is no cumulative damage or effect of clinical significance for either 5 milligrams of tadalafil or 50 milligrams of sildenafil taken daily for six months.”

###

Editor’s Note: This study was supported by Eli Lilly and Company (Bothell, Wash., and Indianapolis). Co-authors Dr. Cordell, Dr. Costigan, Dr. Sides and Ms. Klise report being employees of Eli Lilly and Company. Co-authors Dr. Coupland, Dr. Danis, Dr. Marmor, Dr. Maturi and Dr. Weleber report being paid consultants to Eli Lilly and Company. Dr. Antoszyk and Dr. McGettigan report no financial disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Contact: Eric Schoch

317-274-8205
JAMA and Archives Journals

RELATED STORIES:
Unprotected sex more likely in serious gay relationships   Jailed women seen to need sexual health services   Over a third of former American Football players interviewed had sexual relations with men   Poor fit may explain why men refuse condoms   Does Psychological Treatment for Adult Sex Offenders Work?   Penile extender increased flaccid length by almost a third says independent clinical study   Postnatal health and sexual problems persist at 12 months, but races experience different levels   Men worry more about penile size than women, says 60-year-old research review   Impotence common in men with sleep apnea   Maxi-K Gene Transfer may Prove to be Safe and Effective Erectile Dysfunction Treatment   Freshman women’s binge drinking tied to sexual assault risk   Understanding the process of homosexual identity formation among Asian and Pacific Islander youth   Better HIV Prevention Interventions Needed for Juvenile Offenders   More STDs for Older Widowers in ED Drug Era   Global sex survey shows men get more satisfaction

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]